Replimune Group, Inc. (REPL)
| Market Cap | 1.63B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.16M |
| Shares Out | 49.38M |
| EPS (ttm) | -1.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $35.05 |
| Previous Close | $34.69 |
| Change ($) | 0.36 |
| Change (%) | 1.04% |
| Day's Open | 35.21 |
| Day's Range | 34.05 - 36.35 |
| Day's Volume | 281,514 |
| 52-Week Range | 17.50 - 54.85 |
WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...
WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today annou...
Event to begin at 8:00 AM ET Event to begin at 8:00 AM ET
Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.
Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2
Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...
WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...
WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...
WOBURN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...
RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across al...
Replimune is developing a handful of oncolytic immunotherapies therapies targeting cancers. The company has nearly half a billion dollars in cash.
One has a better chance to keep climbing than the other does.
RP1 : Updated deep and durable response data with Opdivo ® in CSCC and anti- PD1 failed melanoma continue to support ongoing registration-directed development
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
BOSTON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced t...
BOSTON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced a...
WOBURN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced ...
WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today anno...
The company plans to present encouraging early-stage clinical data at a major conference next month.
I nitial safety and efficacy data from the single agent RP2 portion of the Phase 1 clinical trial of RP2 alone & in combination with Opdivo® ( nivolumab ) in patients with solid tumors
WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today annou...
Clinical proof of principle established with RP1 in combination with Opdivo® for the treatment of immune-responsive tumors supporting registration directed development in CSCC and anti-PD1 refractory me...
WOBURN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...
WOBURN, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today an...
WOBURN, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...
Replimune (REPL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
WOBURN, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic™ platfo...
WOBURN, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today an...
RP1: Registration-directed randomized controlled Phase 2 clinical trial of RP1 in combination with cemiplimab-rwlc (Libtayo®) in cutaneous squamous cell carcinoma (CSCC) underway
WOBURN, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...
Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer
WOBURN, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today ann...
Did you know that the GuruFocus All-in-One Screener can be used to find insider trades from a specific period of time or a certain range of value?
BOSTON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced...
BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced...
Data demonstrate RP1 alone and combined with Opdivo® is well tolerated with anti-tumor efficacy in target tumor types
Replimune’s second product candidate to enter the clinic is an Immulytic™ that expresses an anti-CTLA-4 antibody-like protein Replimune’s second product candidate to enter the clinic is an Immulytic™ th...
Abstract highlights initial data from Phase 1 part of Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo® (nivolumab) Abstract highlights initial data from Phase 1 part of Phase 1/2 cl...
Shares have lost 4% of their value since my April article.
Share price performance is relatively flat since July 2018 IPO.
Replimune Group Inc (NASDAQ: REPL)'s lead asset is expected to quickly pass through development and clear the FDA hurdle, according to Wedbush.
About REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, wh... [Read more...]
| Industry Biotechnology | IPO Date Jul 20, 2018 |
| CEO philip Astley-Sparke | Employees 122 |
| Stock Exchange NASDAQ | Ticker Symbol REPL |
Analyst Forecasts
According to 10 analysts, the average rating for REPL stock is "Buy." The 12-month stock price forecast is 56.30, which is an increase of 60.63% from the latest price.